ADIL
Adial Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.12
+6.91%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | 564.00 | — |
| Gross Profit | — | — | — | (564.00) | — |
| Operating Expenses | |||||
| R&D Expense | 2.0M | 2.6M | 3.2M | 1.3M | 2.0M |
| SG&A Expense | 9.5M | 5.2M | 5.1M | 5.6M | 8.9M |
| General & Admin Expense | 9.5M | 5.2M | 5.1M | 5.6M | 8.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 46.2M | — | — | (564.00) | — |
| Total Operating Expenses | 57.7M | 7.8M | 8.3M | 6.9M | 10.9M |
| Cost and Expenses | 57.7M | 7.8M | 8.3M | 6.9M | 10.9M |
| Operating Income (EBIT) | (57.7M) | (7.8M) | (8.3M) | (6.9M) | (10.9M) |
| Non-Operating | |||||
| Interest Income | 195.5K | 149.6K | 178.7K | 69.8K | 63.3K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 195.5K | 149.6K | 178.7K | 69.8K | 63.3K |
| Other Non-Op Income/Expense | (125.3K) | (177.7K) | (4.9M) | (113.9K) | 63.3K |
| Non-Operating Income (excl Interest) | 125.3K | 177.7K | 4.9M | 113.9K | (63.3K) |
| EBT (Pre-Tax Income) | (57.8M) | (8.0M) | (13.2M) | (7.0M) | (10.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (57.8M) | (8.0M) | (13.2M) | (7.0M) | (12.7M) |
| Earnings from Cont. Ops | (57.8M) | (8.0M) | (13.2M) | (7.0M) | (10.8M) |
| Earnings from Discont. Ops | — | — | — | — | (1.9M) |
| Bottom Line Net Income | (57.8M) | (8.0M) | (13.2M) | (7.7M) | (12.7M) |
| Per Share | |||||
| Basic EPS | ($16.53) | ($11.93) | ($17.75) | ($136.00) | ($299.50) |
| Diluted EPS | ($16.53) | ($11.93) | ($17.75) | ($136.00) | ($299.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.6M | 668630 | 743550 | 56986 | 42521 |
| Diluted Shares Outstanding | 4.6M | 668630 | 743550 | 56986 | 42521 |
| Profitability Metrics | |||||
| EBITDA | (57.8M) | (8.0M) | (13.2M) | (7.0M) | (10.8M) |
| D&A | 424.00 | 565.00 | 565.00 | 564.00 | 564.00 |
| EBIT | (57.8M) | (8.0M) | (13.2M) | (7.0M) | (10.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026